Drugs / ROTAVAC 5D
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03602053 | Jan → Oct 2019 | Rotavirus infection, diarrheal disease | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06200844 | Jul 2023 → Jan 2025 overdue | Rotavirus infection | Bharat Biotech International Limited | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05958771 Comparator | Jul 2023 → Feb 2026 | Rotavirus infection | University of Chile | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROTAVAC 5D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05958771 ↗ |
| Known as | 116E | “The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.” NCT06200844 ↗1“The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.” NCT05958771 ↗ |
| Modality | Vaccine | “new Rotavirus vaccine” NCT03602053 ↗ |
| Route | Oral | “0.5 ml of the vaccine will be administered orally” NCT03602053 ↗ |